However, due to recent advances in understanding molecular biology of HNSCC, it is reasonable to believe that targeted therapies using other molecular targets such as HER2 and HER3 that have been approved by the FDA for treatment of other cancers such as breast cancer, metastatic gastric cancers, and metastatic non-small cell lung cancer could be investigated for applicability to HNSCC (24–26). The gene discussed is ERBB2; the disease is cancer.